In the last three years, amyloid plaque-busting drugs Aduhelm (now discontinued) and Leqembi have been approved by the FDA for treating patients in the…
About 89 million Americans use smartwatches and other fitness trackers to measure their fitness levels, sleep, and weight. Soon, there will be apps that…
The monoclonal antibody drugs targeting the brain’s amyloid plaques dominated the news cycle in 2023. Eisai and Biogen’s Leqembi was approved by the FDA…
The Food and Drug Administration has decided to postpone its decision on the approval of Eli Lilly’s candidate Alzheimer’s drug, donanemab. The delay has…
Heard of probiotics? They’re those pills — often found in a refrigerated section of the vitamins aisle at your local pharmacy or natural grocer…
Alzheimer’s disease affects millions of people worldwide, and as the world’s population ages, that number is going up. But, the exact cause of Alzheimer’s…
Fasting diets: They’re all the rage. Across the internet and at bookstore after bookstore, you can find experts promising that a diet that involves…
The internet is abuzz with claims that biomarker blood tests are the key to predicting dementia 15 years out. Indeed, up to now, the…
This week Being Patient did an extensive series of reports on blood tests for Alzheimer’s, because beyond the headlines, there are a lot of…
Nothing is more exciting than when my favorite basketball team, the Toronto Raptors, announced that they were signing a star player that could help…
An Alzheimer’s blood biomarker test can’t actually determine whether or not a person has Alzheimer’s disease — but it can help signal to doctors…
Alzheimer’s blood tests: a new frontier in neurodegenerative diagnostics, getting the world a big step closer to earlier, more accessible Alzheimer’s diagnosis. But it’s…
What causes Alzheimer’s disease and related forms of progressive dementia? Scientists still don’t know. One leading theory points to beta-amyloid protein — a biomarker…
About 14 of every 100 of Black Americans older than 65 have Alzheimer’s disease, compared 10 in 100 white Americans of the same age…
The process of finding new treatments for Alzheimer’s disease is one of trial and error — and every “failed” trial generates invaluable new data…